The introduction of adjuvant anti-HER-2 antibody treatment, trastuzumab, with low presumed efficiency in the CNS, may have altered the natural history of patients with HER-2-positive breast cancer and unmasked CNS as a potential sanctuary site (Lin and Winer, 2007). Here, ERBB2 is linked to breast cancer.